Raymond James Financial Inc. Invests $2.22 Million in INmune Bio, Inc. (NASDAQ:INMB)

Raymond James Financial Inc. purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 475,551 shares of the company's stock, valued at approximately $2,221,000. Raymond James Financial Inc. owned approximately 2.15% of INmune Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in INMB. State Street Corp grew its holdings in shares of INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company's stock worth $1,220,000 after buying an additional 58,838 shares in the last quarter. XTX Topco Ltd purchased a new stake in INmune Bio in the 3rd quarter worth approximately $249,000. Westside Investment Management Inc. raised its holdings in INmune Bio by 57.3% in the 3rd quarter. Westside Investment Management Inc. now owns 71,315 shares of the company's stock valued at $384,000 after acquiring an additional 25,975 shares during the last quarter. Barclays PLC raised its holdings in INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock valued at $157,000 after acquiring an additional 24,906 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of INmune Bio by 6.6% during the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company's stock worth $1,857,000 after purchasing an additional 21,262 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Stock Down 3.7 %

Shares of NASDAQ INMB traded down $0.30 during midday trading on Thursday, hitting $7.77. The stock had a trading volume of 214,583 shares, compared to its average volume of 245,607. INmune Bio, Inc. has a 1-year low of $4.32 and a 1-year high of $12.72. The company has a market capitalization of $206.61 million, a price-to-earnings ratio of -3.56 and a beta of 1.93. The company has a fifty day moving average price of $8.46 and a 200 day moving average price of $6.43.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. On average, research analysts forecast that INmune Bio, Inc. will post -2.24 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Rodman & Renshaw assumed coverage on INmune Bio in a research report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price objective for the company. RODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a report on Tuesday, January 28th. Maxim Group raised their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, Scotiabank upped their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, February 11th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.